Exscientia starts trials of AI-designed Alzheimer’s drugExscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the Share XExscientia starts trials of AI-designed Alzheimer’s drughttps://pharmaphorum.com/news/exscientia-starts-clinical-trials-of-ai-designed-alzheimers-drug/
Sumitomo, Roivant close $3 billion deal, forming SumitovantA new international biotech – Sumitovant Biopharma – has been created after Sumitomo Dainippon’s strategic alliance with Roivant Share XSumitomo, Roivant close $3 billion deal, forming Sumitovanthttps://pharmaphorum.com/news/sumitomo-roivant-close-3-billion-deal-forming-sumitovant/
Sumitomo and Roivant put flesh on bones of $3bn R&D dealSix weeks after Sumitomo Dainippon Pharma agreed a $3 billion deal to license a host of drug candidates Share XSumitomo and Roivant put flesh on bones of $3bn R&D dealhttps://pharmaphorum.com/news/sumitomo-and-roivant-put-flesh-on-bones-of-3bn-rd-deal/
Sumitomo Dainippon bolts on pipeline via $3bn Roivant allianceVivek Ramaswamy’s Roivant group has forged its biggest and most wide-ranging alliance to date, licensing dozens of drugs Share XSumitomo Dainippon bolts on pipeline via $3bn Roivant alliancehttps://pharmaphorum.com/news/sumitomo-dainippon-bolts-on-pipeline-via-3bn-roivant-alliance/
